

Marks&Clerk MXC

Intellectual Property Services



































Cancer: from Cause to Cure

Innovative Healthcare 2013

at the Binding Site

8 Calthorpe Rd, Birmingham B15 1QT Wednesday 25 September 2013

Twitter #scicap

www.sciencecapital.co.uk



16:30 Business plan presentation

Defang Ouyang, Aston University

17:30 Drinks & Canapé Reception

18:00 Introduction by Helen Waterman, Binding Site

18:05 Talks by:

Malcolm Skingle

Sanj Kumar

Jo Morris

Peter Sadler

Andy Pitt

Charlie Craddock

19:30 Panel discussion

20:00 Networking over food and drinks

21:00 Close



Malcolm Skingle, Director, Academic European Liaison at GlaxoSmithKline, on competing on the international stage of drug discovery through collaboration and partnership.



Sanj Kumar, Sr. Vice President and General Manager at DiscoveRx, on taking new technologies for drug discovery from inception to market.



Jo Morris, School of Cancer Sciences, University of Birmingham on breast cancer genetics and target discovery.



Peter Sadler, Professor in Chemistry at the University of Warwick, on innovative precious metal cancer therapy.



Andy Pitt, Professor in Pharmaceutical Chemistry & Chemical Biology at Aston University on target identification and therapy validation by post genomic technologies.



Charlie Craddock, Professor and Director of the Centre for Clinical Haematology at the University of Birmingham and University Hospitals Birmingham on establishing the Institute for Translational Medicine.